Abstract
It is a pleasure to have the opportunity of participating in this conference on antiviral therapy honoring Dr. Dorland Davis, who is leaving the National Institutes of Health after a long and distinguished career. Unfortunately, I am at a double disadvantage as compared with other participants. I have no data to present; moreover, everyone surely knows that my opinions on antiviral agents are suspect since I have been tainted by association with the lobby. Perhaps Dr. Merigan needed a token vaccine lobbyist and a token Food and Drug Administration regulator and saw me as a way to get both for a bargain price!
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
